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Abstract: Venoms are a rich source of potential lead compounds for drug discovery, and descriptive
studies of venom form the first phase of the biodiscovery process. In this study, we investigated the
pharmacological potential of crude Pseudocerastes and Eristicophis snake venoms in haematological
disorders and cancer treatment. We assessed their antithrombotic potential using fibrinogen throm-
boelastography, fibrinogen gels with and without protease inhibitors, and colourimetric fibrinolysis
assays. These assays indicated that the anticoagulant properties of the venoms are likely induced
by the hydrolysis of phospholipids and by selective fibrinogenolysis. Furthermore, while most
fibrinogenolysis occurred by the direct activity of snake venom metalloproteases and serine proteases,
modest evidence indicated that fibrinogenolytic activity may also be mediated by selective venom
phospholipases and an inhibitory venom-derived serine protease. We also found that the Pseudo-
cerastes venoms significantly reduced the viability of human melanoma (MM96L) cells by more than
80%, while it had almost no effect on the healthy neonatal foreskin fibroblasts (NFF) as determined
by viability assays. The bioactive properties of these venoms suggest that they contain a number of
toxins suitable for downstream pharmacological development as candidates for antithrombotic or
anticancer agents.
Keywords: venom; Pseudocerastes; Eristicophis; biodiscovery; melanoma; cancer; cytotoxic; haemo-
toxic; thrombosis; fibrinogenolysis
1. Introduction
Snake venoms are bioactive secretions that consist mainly of proteinaceous and pep-
tidic toxins, which evolved for use in antagonistic interactions, such as predation and
defence [1]. Venom toxin homologues are naturally expressed in body fluids and tissues,
and it is thus believed that toxins descend from genes encoding physiological proteins, such
as those involved in homeostasis [2]. As a reflection of this ancestry, many venom toxins
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possess high potency and specificity for their molecular targets [3,4]. This targeted activity
constitutes essential criteria in drug design. Accordingly, venoms are rich reservoirs of po-
tential lead compounds. Utilising venoms for biodiscovery is a rapidly growing field with
numerous proven successes. For example, enalapril, eptifibatide, tirofiban and batroxobin,
all derived from the venoms of vipers, are FDA-approved drugs used for the treatment
and/or diagnosis of cardiovascular and haematological disorders [5]. Descriptive studies
of venom activity are essential for biodiscovery, yet due to the diversity of venomous
snakes and the complexity of their venom, it is estimated that fewer than 0.01% of snake
venom compounds have been characterised [6].
The desert vipers of the genera Pseudocerastes and Eristicophis (Viperidae: Viperinae)
are an understudied clade. The limited research devoted to characterising their venoms
has described haemolysis and oedema [7], inhibition of platelet aggregation [8,9] and
procoagulant activity [10,11] by E. macmahonii venom, and anticoagulant and haemorrhagic
activity [12], platelet aggregation [13] and cytotoxicity [14] by P. persicus venom. Only one
study to date has described the venom of P. urarachnoides, which is a potent procoagulant
by activating both factor X and prothrombin [11]. The activities of these venoms largely
adhere to the coagulopathic pathophysiology that is characteristic of viper envenoming.
In contrast, presynaptic neurotoxic phospholipase A2 proteases dominate the venom of
P. fieldi, along with absent or very weak coagulopathic activity [12,15–17] and anticoagulant
properties in some animal plasmas [11]. Furthermore, P. persicus and P. fieldi venoms
have also been found to possess extremely low levels of human factor X and prothrombin
activation [11], though their action on human plasma manifests as anticoagulant and
the underlying mechanisms are unexplored. Proteomic comparisons corroborated the
differential activities among these species’ venoms by revealing extensive variations in
their venom protein profiles [11,18].
The wide divergences in venom chemistry within this clade of vipers reflect the
underlying evolutionary processes that may have generated biochemical novelty and raises
interest for their pharmacological potential. This study sought to explore the venoms for
their anticancer properties by assessing their cytotoxicity against the melanoma patient-
derived cell line MM96L and healthy skin cell line NFF. In parallel, we investigated their
antithrombic potential by incubating the venoms with human plasma and fibrinogen
under a range of conditions in colourimetric fibrinolysis assays, thromboelastograms
and fibrinogen gels. The venoms showed promise as anticancer or antithrombotic agent
candidates, and this study provides the foundation to explore their potential further.
2. Results and Discussion
2.1. Venom Profile
2.1.1. Proteomics
The protein profiles of the venoms used were previously assessed using 1D SDS-
PAGE and mass spectrometry analyses on 2D SDS-PAGE gel spots (Table 1) [11,18]. It was
found that, while most toxin groups are conserved among venoms, protein abundances
varied considerably. The venoms of P. urarachnoides and E. macmahonii possess a protein
profile typical of vipers, with numerous isoforms of snake venom serine proteases (SVSP),
metalloproteases (SVMP), L-amino acid oxidases (LAAO) and lectins. In contrast, P. fieldi
venom is dominated by phospholipase A2s (PLA2), while P. persicus comprises mostly
SVMPs and PLA2s. Each venom possesses an abundance of dimers or trimers.
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Table 1. Toxin classes identified following mass spectrometric analyses of desert viper 2D SDS-PAGE venom profiles [11,18].
Toxin Type E. macmahonii P. fieldi P. persicus P. urarachnoides
CRiSP X X X n.d.
Disintegrin X n.d. n.d. n.d.
SVSP X X X X
Kunitz peptide n.d. X X n.d.
LAAO X n.d. n.d. X
Lectin X X X X
Natriuretic peptides n.d. n.d. n.d. n.d.
NGF n.d. X X n.d.
Nucleotidase n.d. X n.d. n.d.
PLA2 X X X X
SVMP X n.d. X X
VEGF X X X n.d.
CRiSP = Cysteine-rich secretory protein; SVSP = Snake venom serine protease; LAAO = L-Amino acid oxidase; NGF = Nerve growth factor;
PLA2 = Phospholipase A2; SVMP = Snake venom metalloprotease; VEGF = Vascular endothelial growth factor; n.d. not detected.
2.1.2. Protease Activity
The venoms varied substantially in their activity on fluorogenic substrates (Figure 1)
in corroboration with their proteomic profile [11,18]. The extent of phospholipase and
metalloprotease activities is also broadly aligned with the venom content described in prior
proteomic studies [11,18]. Assessment of protease activity revealed that serine proteases
were the most abundant protease component in P. urarachnoides venom while contributing
little to the overall protease activity in the other three venoms assayed. This agreed
with the proteomic analysis for the P. urarachnoides venom, which indicates that serine
proteases are featured to a greater extent than in its congeners’ venoms [11]. However, it
was incongruent with the extensive expression of serine proteases earlier documented in
E. macmahonii venom [18]. Further discrepancies between E. macmahonii venom proteome
and protease activity were evident in its apparent lack of PLA2 activity, despite this
toxin class having previously been identified in E. macmahonii venom [18]. However,
vipers commonly express both enzymatic and non-enzymatic isoforms of PLA2s. This
incongruence observed between assay activity and PLA2 abundance may therefore indicate
that E. macmahonii venom expresses predominantly non-enzymatic PLA2 isoforms.
Interestingly, only P. urarachnoides demonstrated activity on the SVMP substrate ES001.
As this substrate is cleaved by collagenases and gelatinases, ES001 cleavage may represent
the degradation of extracellular matrices by haemorrhagic snake venom metalloproteases
(SVMPs). However, in vivo haemorrhagic activity has been observed for the venoms of
E. macmahonii and P. persicus [19], despite their absence of ES001 cleavage. This indicates
that either the mechanisms by which these species induce haemorrhage vary considerably,
or that this substrate is a poor model for haemorrhagic activity. Nevertheless, these assays
provided a basic proxy for assessing the relative functional variation of the enzymes
constituting these venoms, and thus generally support the variability observed in prior
proteomic studies [11,18].




Figure 1. Relative protease activity of Pseudocerastes and Eristicophis venoms on four synthetic sub-
strates for non-comprehensive assessment of snake venom metalloprotease (SVMP) using substrate 
ES001 (light yellow) or ES002 (dark yellow) (crude venom: 0.5 ng/mL), serine protease using sub-
strate ES011 (red) (crude venom: 0.5 ng/mL), or phospholipase (PLA2) (blue) (crude venom: 4 
ng/mL) activities. The data are presented as relative luminescence units (%) normalised to the total 
luminescence detected for all four protease assays combined and are the mean ± SD of four inde-
pendent experiments. 
2.2. Cytotoxicity 
The venoms were tested for their cytotoxic and anticancer properties by incubation 
with human diseased cells (melanoma cell line MM96L) and healthy cells (neonatal fore-
skin fibroblasts (NFF)). At concentrations of 5–50 μg/mL, all Pseudocerastes venoms signif-
icantly reduced the MM96L cell viability and had a minimum effect on NFF cell viability 
(Figure 2A–C). Pseudocerastes persicus venom produced the most striking differential im-
pact on cell viability, in which venom concentrations of 5–50 μg/mL reduced viability of 
at least 84 ± 2% of MM96L cells while over 85 ± 15% of NFF cells remained viable (Figure 
2B). Similarly, 5–50 μg/mL P. urarachnoides venom significantly reduced the viability of 
MM96L cells by at least 80 ± 2%, with over 74 ± 14% NFF cells remaining viable (Figure 
2A). Of note, 50 μg/mL of P. urarachnoides venom decreased MM96L cell viability by 96 ± 
2% yet left 100 ± 0% NFF cells viable. These results demonstrate the potential of Pseu-
docerastes venom compounds to be explored in treatments of melanoma. 
Melanoma is an aggressive form of highly metastatic skin cancer with high resistance 
to chemotherapeutic drugs [20]. We hypothesise that Pseudocerastes venoms may target 
essential signalling cascades for the survival of cells, such as the molecular axis of 
AKT/PI3K/mTOR. The coordination of these pathways modulates anabolic processes re-
sponsible for key components (cholesterol, phospholipids) of the endomembrane system 
and drives the metabolic process that sustains the generation of new cancer cells. In rela-
tion to this, Pseudocerastes venoms may also target the integrity and function of the mito-
chondria, organelles that provide the molecular scaffolds (Acetyl-CoA, amino acids)—
and sometimes part of energy sources—necessary for the proliferation of cancer cells. 
Similar observations were recently made for an Octopus Kaurna-derived peptide, Oc-
tpep-1, which specifically targets melanoma cells and with minimum effect on healthy 
fibroblasts. Octpep-1 exerts its antiproliferative profile by inhibiting the PI3K/AKT/m 
TOR signalling pathway in melanoma cells [21]. In addition, gomesin (spider) peptides 
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substrates for non-comprehensive assessment of snake venom metalloprotease (SVMP) using sub-
strate ES001 (light yellow) or ES002 (dark yellow) (crude venom: 0.5 ng/mL), serine protease using
ubstrate ES011 (red) (crude venom: 0.5 ng/mL), or phospholipase (PLA2) (blue) (crude venom:
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. . i i
ere tested for their cytotoxic and anticancer properties by incuba-
tion with human diseased cells (melanoma cell line MM96L) and ealthy cells (neonatal
foreskin fibroblasts (NFF)). At concentrations of 5–50 µg/mL, all Pseudocerastes venoms
significantly reduced the MM96L cell viability and had a inimum effect on NFF cell
viability (Figure 2A–C). Pseudocerastes persicus venom produced the most striking differ-
ential impact on cell viability, in which venom concentrations of 5–50 µg/mL reduced
viability of at least 84 ± 2% of MM96L cells while over 85 ± 15% of NFF cells remained
viable (Figure 2B). Similarly, 5–50 µg/mL P. urarachnoides venom significantly reduced the
viability of MM96L cells by at least 80 ± 2%, with over 74 ± 14% NFF cells remaining
viable (Figure 2A). Of note, 50 µg/mL of P. urarachnoides venom decreased MM96L cell
viability by 96 ± 2% yet left 100 ± 0% NFF cells viable. These results demonstrate the
potential of Pseudocerastes venom compounds to be explored in treatments of melanoma.
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(data not shown). Venom-treated cell data were tested for normality using Shapiro–Wilk tests, then compared to their 
controls using unpaired t-tests as they were normally distributed. The data are expressed as mean ± SD and are the result 
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Figure 2. Viable human cells (%) after incubation with Pseudocerastes (A–C) and Eristicophis (D) venoms (1, 5, 10, or
50 µg/mL) for 48 h, quantified by MTT assays. Cell viability readings were normalised against vehicle-treated control
cells (data not shown). Venom-treated cell data were tested for normality using Shapiro–Wilk tests, then compared to
their controls using unpaired t-tests as they were normally distributed. The data are expressed as mean ± SD and are the
result of at least three replicates. **** = p < 0.0001, *** = p < 0.001, ** = p < 0.01, ns = no significant difference between
venom-tre ed (data shown) vs. vehicle-trea ed con rol (data not shown) cells. MM96L = elanoma cells, NFF = neonatal
foreskin fibroblasts.
Melanoma is an aggressive form of highly metastatic skin cancer with high resis-
tance to chemotherapeutic drugs [20]. We hypothesise that Pseudocerastes venoms may
target essential signalling cascades for the survival of cells, such as the molecular axis
of AKT/PI3K/mTOR. The coordination of these pathways modulates anabolic processes
responsible for key components (cholesterol, phospholipids) of the endomembrane system
and drives the metabolic process that sustains the generation of new cancer cells. In relation
to this, Pseudocerastes venoms may also target the integrity and function of the mitochondria,
organelles that provide the molecular scaffolds (Acetyl-CoA, amino acids)—and sometimes
part of energy sources—necessary for the proliferation of cancer cells.
Similar observations were recently made for an Octopus Kaurna-derived peptide,
Octpep-1, which specifically targets melanoma cells and with minimum effect on healthy
fibroblasts. Octpep-1 exerts its antiproliferative profile by inhibiting the PI3K/AKT/m
TOR signalling pathway in melanoma cells [21]. In addition, gomesin (spider) peptides
show a similar anti-melanoma pattern with almost no effect on healthy fibroblasts. Specifi-
cally, gomesin peptides diminish the viability of melanoma cells by inhibiting the MAPK
pathway while simultaneously stimulate the HIPPO pathway [22]. In the current study,
the mechanism Pseudocerastes venoms utilise to abolish melanoma cells remains unknown.
However, the data presented in this study as well as in our previous studies and in the litera-
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ture warrants further investigations, with special emphasis on MAPK or PI3K/AKT/mTOR
pathways, due to their significance in melanoma [23].
A cytotoxic effect specific for human melanoma cells was not observed for E. macma-
honii venom, which was consistently equally cytotoxic across both cell lines (p > 0.01) and
consistently reduced viability of at least 70% of cells, even at low concentrations (5 µg/mL)
(Figure 2D). This venom contains large quantities of serine proteases and metalloproteases
along with smaller quantities of L-amino acid oxidases, each of which are commonly
associated with cellular and tissue degradation. However, these toxins are also abundant in
the venom of P. urarachnoides, which displayed selective cytotoxicity between the two cell
lines. This points to key differences within the venom content between the two genera and
suggests that the toxins responsible for the variable cytotoxic activity may have originated
within the common ancestor of Pseudocerastes.
2.3. Coagulant Activity
2.3.1. Coagulation and Fibrinolysis
The venoms assayed in the current study have been previously shown to exert different
haemotoxic activities in human plasma, such as clot inhibition by P. fieldi and P. persicus
and clot stimulation by P. urarachnoides and E. macmahonii [11]. Each venom’s effect on clot
dynamics was assessed to investigate this further. Fibrinolytic toxin activity (the lysis of
fibrin clots as opposed to that of fibrinogen molecules) has been described for the venom
of numerous vipers [24,25] and thus was tested by incubating venoms and human plasma
with and without human tissue factor, which initiates clot formation, and human tissue
plasminogen activator, which initiates clot lysis.
All venoms interfered with the activity of tissue factor and tissue plasminogen ac-
tivator (Figure 3A), and their haemotoxic properties were largely congruent with those
observed in the previous study that analysed these venoms [11]. For example, in the
presence of tissue factor, the anticoagulant P. persicus and P. fieldi venoms prolonged the
time to clot formation, with the latter inducing a low-density clot, indicative of a weakened
clot structure (Figure 3B). In contrast, the procoagulant P. urarachnoides and E. macmahonii
venoms stimulated high-density clots and rapid fibrin clot formation in the absence of a
tissue factor trigger (Figure 3B–D). However, none of the venoms were able to initiate clot
lysis, as indicated by the lack of decrease in optical density over time in the absence of
tissue plasminogen activator (Figure 3B,D).




Figure 3. Plasma clot formation and fibrinolysis of human plasma were followed by turbidity assessment at 405 nm in the 
presence of 0.1 μg/mL Pseudocerastes or Eristicophis venom with (A, B) or without (C, D) tissue factor (TF) and with (A, C) 
or without (B, D) tissue plasminogen activator (tPA), measured over 60 min at 37 °C. Plasma without venom was used as 
a control. The data are the mean ± SD of three independent experiments. 
2.3.2. Phospholipid Interactions 
Interactions between venoms and an anionic phospholipid surface were assessed by 
conducting a PCPS dilution series and measuring lag time (onset of fibrin clot formation), 
time to peak (clot formation rate) and peak (clot density maximum) of clotting via turbid-
ity assessment. There were no significant relationships among anionic phospholipid con-
centration and lag time, time to peak, or clot density in the plasma or thrombin controls 
(p < 0.05 for all relationships) (Figure 4A,B). Increasing phospholipid concentrations be-
tween 3 and100 μM quickened the clotting activity of each Pseudocerastes venom. Notably, 
there was a strong positive relationship between phospholipid concentration and clotting 
function of P. fieldi venom, whereby saturating the venom and plasma with phospholipid 
vesicles abolished the anticoagulant activity (Figure 4D). A similar (though less pro-
nounced) trend was evident within P. persicus test conditions (Figure 4E). This strongly 
suggests that the dominant anticoagulant mechanism of these venoms in human plasma 
Figure 3. Plas a clot for ation and fibrinolysis of human plasma were fol owed by turbidity as es ment at 405 nm in the
presence of 0.1 µg/ Pseudocerastes or Eristicophis venom with (A,B) or without (C,D) tissue factor (TF) and with (A,C) or
without (B,D) tissue plasminogen activator (tPA), measured over 60 min at 37 ◦C. Plasma without venom was used as a
control. The data are the mean ± SD of three independent experiments.
2.3.2. Phospholipid Interactions
Interactions between venoms and an anionic phospholipid surface were assessed by
conducting a PCPS dilution series and measuring lag time (onset of fibrin clot formation),
time to peak (clot formation rate) and peak (clot density maximum) of clotting via turbidity
assessment. There were no significant relationships among anionic phospholipid concentra-
tion and lag time, time to peak, or clot density in the plasma or thrombin controls (p < 0.05
for all relationships) (Figure 4A,B). Increasing phospholipid concentrations between 3 and
100 µM quickened the clotting activity of each Pseudocerastes venom. Notably, there was
a strong positive relationship between phospholipid concentration and clotting function
of P. fieldi venom, whereby saturating the venom and plasma with phospholipid vesicles
abolished the anticoagulant activity (Figure 4D). A similar (though less pronounced) trend
was evident within P. persicus test conditions (Figure 4E). This strongly suggests that the
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dominant anticoagulant mechanism of these venoms in human plasma occurs via antag-
onistic interactions with phospholipids, which play an essential role in the coagulation
cascade [26]. A common anticoagulant mechanism by PLA2s is the hydrolysis of plasma
phospholipids (e.g., [27]), though non-hydrolytic mechanisms have also been reported
(e.g., [26]). Further studies are therefore required to determine the specific interactions
occurring by these venoms.




Figure 4. Plasma clot formation of human plasma was followed by turbidity assessment at 405 nm in the presence of tissue 
factor (6 pM) in the absence or presence of 0.01 μg/μL of Eristicophis (C), Pseudocerastes (D–F) venoms were measured for 
60 min at 37 °C. The lag time (blue circles, left axis), time to peak (red squares, left axis) and peak (optical density at 405 
nm; green triangles, right axis) are shown. Reactions in which venom was replaced by thrombin (0.01 μg/μL) (B) or vehicle 
solution (A) were used as positive and negative controls, respectively. The data are the mean ± SD of three independent 
experiments. # = infinity, i.e., no clot occurred during the 35 min measurement. 
2.3.3. Fibrinogenolytic Activity 
Fibrinogen gels and fibrinogen-only thromboelastograms were conducted to evalu-
ate the fibrinogenolytic activity of venoms. Within the thromboelastography, for venoms 
that did not induce clotting within the first 30 min, thrombin was added to quantify the 
remaining functional fibrinogen. The thromboelastography indicated that none of the 
venoms clot fibrinogen directly. Post hoc addition of thrombin revealed that all four ven-
oms have degradative fibrinogenolytic activity, each reducing both clot strength (maxi-
mum amplitude—millimetres (mm)) and clot formation rate (angle—degrees) (Figure 5). 
Figure 4. Plasma clot formation of human plasma was followed by turbidity assessment at 405 nm in the presence of tissue
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experiments. # = infinity, i.e., no clot occurred during the 35 min measurement.
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The phospholipid had limited effect upon the activity of the E. macmahonii venom
except for a significant reduction in clot peak density over increasing phospholipid concen-
trations, from an optical density (OD) of 0.76 ± 0.02 at 0 µM phospholipid to 0.65 µ 0.01 at
300 µM (non-linear regression: Syx = 0.02893; F-test: F1,12 = 12.94, p = 0.0037) (Figure 4C).
A similar inverse relationship between clot peak and phospholipid concentration was
evident within P. urarachnoides venom conditions (non-linear regression: Syx = 0.05813;
F-test: F1,22 = 3662, p < 0.0001) (Figure 4F). This could be occurring due to a reduction in
fibrin branching or fibrin strand diameter and subsequent fibrin mesh porosity, each of
which is known to be affected by relative concentrations of cofactors, activators and the
rate of fibrinogen cleavage [28].
These data demonstrate the high variability of venoms’ coagulant activity relative to
the chosen model conditions, even within a single plasma. Turbidity measurement of clot
density is commonly used in preclinical venom assessments to determine coagulant activity.
The variability presented by these viper venoms indicates that such methods should be
interpreted with extreme caution by studies relying only on this type of assessment. Such
analyses should be run under a range of conditions to determine the consistency of observed
clotting response and should ideally be paired with additional clotting assays.
2.3.3. Fibrinogenolytic Activity
Fibrinogen gels and fibrinogen-only thromboelastograms were conducted to evaluate
the fibrinogenolytic activity of venoms. Within the thromboelastography, for venoms
that did not induce clotting within the first 30 min, thrombin was added to quantify
the remaining functional fibrinogen. The thromboelastography indicated that none of the
venoms clot fibrinogen directly. Post hoc addition of thrombin revealed that all four venoms
have degradative fibrinogenolytic activity, each reducing both clot strength (maximum
amplitude—millimetres (mm)) and clot formation rate (angle—degrees) (Figure 5).




Figure 5. Reduction (%) of functional human fibrinogen (2 mg/mL) following 30 min of incubation with venom (20 μg/mL), 
assessed by post hoc addition of thrombin with subsequent clotting measured by thromboelastography. Angle represents 
the reduction in the rate of clot formation upon addition of thrombin; maximum amplitude represents the reduction in 
clot strength. Control = fibrinogen incubated for 30 min without venom prior to addition of thrombin. The data represent 
four individual analyses per condition; violin plot shows distribution of data. 
Eristicophis macmahonii venom possessed the strongest fibrinogenolytic activity, pro-
ducing a 38 ± 3% reduction in clot strength compared to the control (unpaired t-test: t(6) 
= 7.901, p = 0.000008), followed by P. urarachnoides venom (33 ± 6% reduction; unpaired t-
test: t(6) = 9.233, p = 0.000091). Pseudocerastes fieldi and P. persicus venoms were comparable 
for fibrinogenolytic activity. This effect was moderate to low, but significant, with a 22 ± 
10% and 18 ± 10% reduction in clot strength, respectively (control vs. P. fieldi unpaired t-
test: t(6) = 3.838, p = 0.008581; control vs. P. persicus unpaired t-test: t(6) = 3.244, p = 
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support the notion that the clot inhibition by these venoms in human plasma is largely 
due to PLA2 interactions with plasma phospholipids, in conjunction with a fibrino-
genolytic activity. 
Analysis of fibrinogenolytic activity using SDS-PAGE indicated that P. persicus 
venom possesses the most rapid fibrinogenolytic activity on the fibrinogen Aα-chain, 
completely degrading this chain within 5 min (Figure 6C). The migration pattern of the 
fibrinogen degradation products suggested a greater similarity in fibrinogen cleavage 
sites between P. urarachnoides (Figure 6D) and E. macmahonii (Figure 6A) venom than be-
tween sister species P. urarachnoides and P. persicus. Pseudocerastes fieldi lacked discernible 
activity in these gels (Figure 6B). The venoms of P. persicus, P. urarachnoides and E. macma-
honii all preferentially cleaved the Aα-chain of fibrinogen, followed by the Bβ-chain. This 
temporal pattern of preferential cleavage follows the dominant cleavage trend amongst 
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gard. 
Figure 5. Reduction (%) of functional human fibrinogen (2 mg/mL) followi g 30 mi of incubation
with venom (20 µg/mL), assessed by post hoc addition of thrombin with subsequent clotting mea-
sured by thromboelastography. Angle represents the reduction in the rate of clot formation upon addi-
tion of thrombin; maximum amplitude represents the reduction in clot strength. Control = fibrinogen
incubated for 30 min without venom prior to addition of thrombin. The data represent four individual
analyses per condition; violin plot shows distribution of data.
Int. J. Mol. Sci. 2021, 22, 6896 10 of 17
Eristicophis macmahonii venom possessed the strongest fibrinogenolytic activity, pro-
ducing a 38 ± 3% reduction in clot strength compared to the control (unpaired t-test:
t(6) = 7.901, p = 0.000008), followed by P. urarachnoides venom (33 ± 6% reduction; un-
paired t-test: t(6) = 9.233, p = 0.000091). Pseudocerastes fieldi and P. persicus venoms were
comparable for fibrinogenolytic activity. This effect was moderate to low, but significant,
with a 22 ± 10% and 18 ± 10% reduction in clot strength, respectively (control vs. P. fieldi
unpaired t-test: t(6) = 3.838, p = 0.008581; control vs. P. persicus unpaired t-test: t(6) = 3.244,
p = 0.017599). These levels of fibrinogenolytic activity were too low to solely account for
the anticoagulant effects of the venoms in plasma. Therefore, these modest reductions
further support the notion that the clot inhibition by these venoms in human plasma
is largely due to PLA2 interactions with plasma phospholipids, in conjunction with a
fibrinogenolytic activity.
Analysis of fibrinogenolytic activity using SDS-PAGE indicated that P. persicus venom
possesses the most rapid fibrinogenolytic activity on the fibrinogen Aα-chain, completely
degrading this chain within 5 min (Figure 6C). The migration pattern of the fibrinogen
degradation products suggested a greater similarity in fibrinogen cleavage sites between
P. urarachnoides (Figure 6D) and E. macmahonii (Figure 6A) venom than between sister
species P. urarachnoides and P. persicus. Pseudocerastes fieldi lacked discernible activity in
these gels (Figure 6B). The venoms of P. persicus, P. urarachnoides and E. macmahonii all
preferentially cleaved the Aα-chain of fibrinogen, followed by the Bβ-chain. This temporal
pattern of preferential cleavage follows the dominant cleavage trend amongst vipers. Such
fibrinogenases are also known to commonly possess haemorrhagic activity [24]. The
fibrinogenolysis observed may thus represent “promiscuous” activity of haemorrhagins,
which have been previously described from the venom of P. persicus and E. macmahonii [19].
Bioactivity testing of venom fractions would be illuminating in this regard.
Within vipers, α-fibrinogenases are typically associated with SVMPs (particularly
the P-I class) and β-fibrinogenases with SVSPs [24]. Post hoc fibrinogen gels conducted
with inhibitors for serine proteases (PMSF), snake venom metalloproteases (EDTA) and
phospholipases (Varespladib) indicated that most of these venoms’ fibrinogenolysis oc-
curs via SVMP activity to the Aα-chain (Figure 7B) with some serine protease activity on
the βB-chain (Figure 7A), congruent with the aforementioned trend observed in viperid
fibrinogenases [24]. A βB-chain serine protease appeared to be present in the venom
of E. macmahonii. An interesting result was observed in the activity of the E. macmahonii
venom with and without PLA2 inhibitor Varespladib (Figure 7C), in which inhibition of
PLA2s appeared to retain a small proportion of the βB-chain. The typical mode of PLA2
activity is the hydrolysis of lipoprotein and cell membrane phospholipids [3]. The prote-
olytic activity of PLA2s on lipid-free proteins has been described [29], though it appears to
be a rare and poorly understood phenomenon. Whether this finding represents a similar,
uncharacteristic PLA2 activity is not clear. This would benefit from further investigation as
it may represent a currently undescribed mechanism of snake venom PLA2s.
Another notable result was observed for P. fieldi, with serine protease inhibition
eliciting fibrinogenolytic activity on the Aα-chain that was not evident in any of the other
conditions assessed. This curious finding could suggest that the venom may contain a serine
protease that inhibits a fibrinogenolytic protein, though this would be extremely unusual.
However, fibrinogenolysis is evident in the thromboelastography. The discrepancy between
the apparent lack of fibrinogenolytic activity without inhibitors (Figure 7B) and the activity
observed in the thromboelastography (Figure 5) may ultimately be explained by the
putative serine protease involved—though precisely how this may be occurring is puzzling
and would benefit from a comprehensive investigation.
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Figure 7. Activity of Eristicophis and Pseudocerastes venoms on human fibrinogen (0.5 μg/mL venom in 1 mg/mL fibrinogen) 
after 20 min of incubation at 37 °C, with (+) and without (–) inhibitors for (A) serine proteases (1 mM PMSF); (B) metallo-
proteases (10 mM EDTA) and (C) phospholipases (10 mM Varespladib). fib = fibrinogen control (no venom), mac = E. 
macmahonii, fiel = P. fieldi, pers = P. persicus, ura = P. urarachnoides. 
Another notable result was observed for P. fieldi, with serine protease inhibition elic-
iting fibrinogenolytic activity on the Aα-chain that was not evident in any of the other 
conditions assessed. This curious finding could suggest that the venom may contain a 
serine protease that inhibits a fibrinogenolytic protein, though this would be extremely 
unusual. However, fibrinogenolysis is evident in the thromboelastography. The discrep-
ancy between the apparent lack of fibrinogenolytic activity without inhibitors (Figure 7B) 
and the activity observed in the thromboelastography (Figure 5) may ultimately be ex-
plained by the putative serine protease involved—though precisely how this may be oc-
curring is puzzling and would benefit from a comprehensive investigation. 
3. Materials and Methods 
3.1. Venom Samples 
Venom samples from the same snake species were pooled to account for any poten-
tial variation in toxin expression between individuals. Eristicophis macmahonii venom was 
collected from three adult male snakes from the Nushki district (30.12° N 67.01° E) of Bal-
ochistan, Pakistan. Pseudocerastes urarachnoides venoms were collected in Iran under the 
approval of NIMAD # 942485. Pseudocerastes fieldi and P. persicus (Pakistan) venoms were 
purchased from Latoxan (Portes-lès-Valence, France). All venom work was undertaken 
under the University of Queensland IBSC approval #IBC134BSBS2015. The lyophilised 
venoms were reconstituted to a working stock concentration of 1 mg/mL in 50% deionised 
water (diH2O) and 50% glycerol (>99.5% purity, Sigma-Aldrich, St Louis, MO, USA) to 
A.     +/− PMSF
fib mac fiel pers ura fib fib mac fiel pers ura fib
B.     +/− EDTA
fib mac fiel pers ura fib
C.     +/− Varespladib
Figure 7. Activity of Eristicophis and Pseudocerastes venoms on human fibrinogen (0.5 µg/mL venom in 1 mg/mL fib-
rinogen) after 20 min of incubation at 37 ◦C, with (+) and without (–) inhibitors for (A) serine proteases (1 mM PMSF);
(B) metalloproteases (10 mM EDTA) and (C) phospholipases (10 mM Varespladib). fib = fibrinogen control (no venom),
mac = E. macmahonii, fiel = P. fieldi, pers = P. persicus, ura = P. urarachnoides.
3. Materials and Methods
3.1. Venom Samples
Venom amples from the same snake spe ies w re po led to account for any potential
variation in toxin expressio between individuals. E isticophis macma onii v nom was
collected from three adult male snakes from the Nushki d strict (30.12◦ N 67.01◦ E) of
Balochistan, Pakistan. Pseudocerastes urarachnoides venoms we collected in Ir n und r the
approval of NIMAD # 942485. Pseudocerastes fieldi and P. persicus (Pakistan) venoms were
purchased from Latoxan (Portes-lès-Valence, France). All ve om work was undertaken
under the University of Queensland IBSC approval #IBC134BSBS2015. The lyophilised
venoms were reconstituted to a working stock concentration of 1 mg/mL in 50% deionised
water (diH2O) and 50% glycerol (>99.5% purity, Sigma-Aldrich, St. Louis, MO, USA) to
reduce enzyme degradation associated with freeze–thaw cycles. These working stock
aliquots were stored at −20 ◦C and used for all subsequent analyses.
3.2. Fluorometric Enzyme Activity Assays
Fluorescence assays were performed using a Fluoroskan Ascent™ Microplate Fluo-
rometer with Ascent®Software v2.6 (Thermo Fisher Scientific, Vantaa, Finland). For these
assays, venom working stocks were diluted to the desired concentration in dilution buffer:
150 mM NaCl, 50 mM Tris-HCl, pH 7.4, unless otherwise stated.
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3.2.1. Snake Venom Phospholipase A2 Activity (PLA2)
The phospholipase A2 (PLA2) activity of the venoms was assessed using an EnzChek®
Phospholipase A2 Assay Kit (Thermo Fisher Scientific, Rochester, NY, USA). Briefly, 10 µL
venom (0.01 µg/µL) was brought up to 12.5 µL in PLA2 reaction buffer (250 mM Tris-HCL,
500 mM NaCl, 5 mM CaCl2, pH 8.9) and loaded in triplicate on a 384-well plate. In each
well, 12.5 µL quenched 1 mM EnzChek® Phospholipase A2 substrate was added (total
volume 25 µL/well), and the run was immediately initiated. Fluorescence was measured
for 100 cycles at an excitation of 485 nm and emission of 520 nm at room temperature.
A negative control consisted of 12.5 µL PLA2 reaction buffer and 10 µL substrate and a
positive control of 12.5 µL PLA2 reaction buffer and 10 µL kit-provided bee venom.
3.2.2. Snake Venom Metalloprotease (SVMP) Activity
Ten microlitres of venom (0.05 µg/µL) was plated in triplicate on a 384-well plate.
Negative or vehicle control consisted of 10 µL dilution buffer. Machine incubation tem-
perature was set at 37 ◦C. The plate was loaded, and 90 µL quenched substrate was
automatically dispensed (10 µL substrate (Fluorogenic Peptide Substrate Cat#ES001; R&D
systems, Minneapolis, MN, USA)) in 5 mL enzyme buffer (150 mM NaCl, 50 mM Tris-HCl,
5 mM CaCl2, pH 7.4). Fluorescence was monitored at an excitation of 390 nm and emission
of 460 nm for 400 cycles or until activity ceased. The assay was repeated using Fluoro-
genic Peptide Substrate Cat#ES002 (R&D systems, Minneapolis, MN, USA) under identical
test conditions.
3.2.3. Snake Venom Serine Protease (SVSP) Activity
Test conditions were identical as those for testing SVMP activity, except that Fluoro-
genic Peptide Substrate Cat#ES0011 (R&D systems, Minneapolis, MN, USA) was used and
fluorescence was monitored at 320 nm (excitation) and 405 nm (emission).
3.3. Cytotoxicity
Human neonatal foreskin fibroblast (NFF) and human malignant melanoma (MM96L)
cell lines were previously established from patients according to approved ethical proce-
dures and standards of use and compliance by the QIMR Berghofer MRI Human Research
Ethics Committee (HREC) under project approval P949. Cells were maintained in RPMI
medium supplemented with 1% penicillin–streptomycin and foetal calf serum (FCS),
10% FCS for NFF and 5% FCS for MM96L. Cells were split 24 h prior to the experiment
using 0.25% trypsin and seeded in 96-well flat-bottom plates at a density of 5000 and
2500 cells/well for NFF and MM96L cells, respectively. Plates were incubated overnight at
37 ◦C in a 5% CO2-95% humidified environment prior to treatment.
MTT Assays
Cell viability was evaluated using colourimetric MTT (Thiazolyl Blue Tetrazolium
Bromide; Sigma-Aldrich, St. Louis, MO, USA) assays and as previously described [30].
Briefly, 50 µg/mL, 10 µg/mL, 5 µg/mL, or 1 µg/mL of venom was added to cells (n = 4)
and incubated for 48 h. Subsequently, MTT (5 mg/mL) was added to each well. Ten
percent sodium dodecyl sulphate (SDS) was used as a positive control (100% toxicity), and
absorbance was read at 570 nm. Three independent experiments were performed with a
minimum of three replicates per treatment. Cell viability readings were normalized against
untreated control cells and subtracted from wells containing only media.
3.4. Venom-Induced Coagulant Activity
3.4.1. Fibrinolysis
Small unilamellar phospholipid vesicles (PCPS) composed of 75% (w/w) hen egg
L-α-phosphatidylcholine and 25% (w/w) porcine brain L-α-phosphatidylserine (Avanti
Polar Lipids, Alabaster, AL, USA) were prepared and characterized as described [31]. For
the fibrinolysis assay, 6 pM tissue factor (TF) (Innovin®, Siemens Healthcare Diagnostics,
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NY, USA) and 10 µM PCPS were maintained at 37 ◦C for one hour in HEPES buffer (25 mM
HEPES, 137 mM NaCl, 3.5 mM KCl, 0.1% BSA (Bovine Serum Albumin A7030, Sigma
Aldrich, St. Louis, MO, USA), pH 7.4). Following this, 17 mM CaCl2 and 37.5 U/mL
tissue plasminogen activator in dilution buffer were added. To measure the fibrinolytic
activity of venoms, 30 µL of the reaction mix, 10 µL of HEPES buffer and 10 µL of venom
at three concentrations (0.01 µg/µL, 0.05 mg/µL, 0.1 µg/µL) were loaded in triplicate into
a 96-well plate. Control wells were loaded following the same experimental protocol, with
the substitution of tissue factor and/or tissue plasminogen activator by equal volumes of
HEPES buffer. Fifty microlitres of normal human platelet-poor pooled plasma (3.2% (w/v)
sodium citrate) (Sanquin, Amsterdam, The Netherlands) was loaded into each well, and
the clot formation and subsequent lysis were monitored by measuring the optical density
at 405 nm every 30 s for 3 h at 37 ◦C on a Spectra Max M2e microplate reader using Softmax
Pro software (Molecular Devices, Sunnyvale, CA, USA).
3.4.2. Phospholipid Interactions
Interactions between venom and anionic phospholipid vesicles on fibrin clot formation
were conducted as per fibrinolysis assays, but without the addition of tissue plasminogen
activator to venom wells and with an extended concentration range of PCPS across wells
(serial dilution: 0, 1, 3, 10, 30, 100 and 300 µM). Reactions in which venom was replaced by
thrombin (0.01 µg/µL) were used as a positive control. The lag time was defined as the
time point at which the optical density at 405 nm increased (delta absorbance >0.04); the
peak time was the time at maximum optical density.
3.4.3. Fibrinogenolysis
One millimolar 12% SDS-PAGE gels were prepared using pre-established protocols
and reagents described in op den Brouw et al. [11]. Human fibrinogen was reconstituted to
a concentration of 2 mg/mL in isotonic saline solution, flash-frozen in liquid nitrogen and
stored at −80 ◦C until use. The following assay was conducted in triplicate for each venom:
five aliquots containing 10 µL reducing buffer (5 µL of 4× Laemmli sample buffer (Bio-Rad,
Hercules, CA, USA), 5 µL diH2O, 100 mM DTT (Sigma-Aldrich, St. Louis, MO, USA))
were prepared. Then, a stock aliquot of 50 µL fibrinogen (1 mg/mL in buffer: 150mM
NaCl, 50 mM TrisHCl, 5mM CaCl, pH 7.4) was warmed to 37 ◦C in an incubator. Once
warmed, 10 µL was removed from the stock aliquot and added to one of the prepared
aliquots, manually mixed and boiled at 100 ◦C for 4 min to represent the “0 min incubation”
fibrinogen control. Four microlitres of venom (1 mg/mL) was added to the stock aliquot of
fibrinogen (amounting to approximately 0.1 mg/mL of venom and 1 mg/mL of fibrinogen
in 40 µL total volume), mixed and immediately returned to the incubator for the duration
of the assay. At each incubation time period (1, 5, 20 and 60 min), 10 µL was taken from
the stock aliquot, added to an aliquot containing 10 µL reducing buffer, pipette mixed and
boiled at 100 ◦C for 4 min. These aliquots were then loaded into the gels and run using 1×
gel running buffer at room temperature for 20 min at 90 V (Mini Protean3 power-pack from
Bio-Rad, Hercules, CA, USA) and then 120 V until the dye front approached the bottom
of the gel. Gels were stained with colloidal coomassie brilliant blue G250 (34% methanol
(VWR Chemicals, Tingalpa, QLD, Australia), 3% orthophosphoric acid (Merck, Darmstadt,
Germany), 170 g/L ammonium sulphate (Bio-Rad, Hercules, CA, USA), 1 g/L coomassie
blue G250 (Bio-Rad, Hercules, CA, USA) and de-stained in diH2O.
Fibrinogen gels were run with and without the SVMP inhibitor Ethylenediaminete-
traacetic acid (EDTA) (Sigma Aldrich, St. Louis, MO, USA) (10 mM), the serine protease
inhibitor phenylmethylsulphonyl fluoride (PMSF) (Sigma Aldrich, St. Louis, MO, USA)
(1 mM in isopropanol) and the PLA2 inhibitor Varespladib (Sigma-Aldrich, St. Louis, MO,
USA) (10 mM in DMSO) to investigate the comparative fibrinogenolytic activity of SVMP,
SVSP and PLA2 toxin classes. Testing conditions were identical to those for fibrinogen gels
without inhibitors, except 5 µL venom (1 mg/mL) or 5 µL buffer (negative control) was
added to 5 µL fibrinogen (2 mg/mL) with/without 1 µL inhibitor and incubated for 20 min
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only. This increase in venom concentration and decrease in total incubation time was to
account for the rapid half-life (15–60 min) of PMSF.
The effects of the venoms on the fibrinogen were quantified using a Thromboelastograph®
5000 Haemostasis analyser (Haemonetics®, Haemonetics Australia Pty Ltd., Sydney, Aus-
tralia). Human fibrinogen (Sigma Aldrich, St. Louis, MO, USA) was reconstituted to
a concentration of 4 mg/mL in isotonic saline solution (150mM NaCl, 50mM Tri-HCl
(pH 7.3)), flash-frozen in liquid nitrogen and stored at −80 ◦C until use. In quadruplicate,
189 µL of fibrinogen was combined with 72 µL CaCl2 (25 mM stock solution Stago Cat#
00367 STA, Asniéres sur Seine, France), 72 µL phospholipid (STA C·K Prest standard kit,
Stago Cat# 00597, Asniéres sur Seine, France; solubilised in Owren Koller (OK) buffer
(Stago, Asniéres sur Seine, France)), and 20 µL OK buffer in an assay cup (Haemonetics
Australia Pty Ltd., North Rye, Sydney, Australia). Then 7 µL of venom working stock (1
mg/mL) was added to the cup, pipette mixed and the machine was immediately started.
Tests were run at 37 ◦C and measured for 30 min. If no clots were formed by the ven-
oms, 7 µL thrombin (STA®-Liquid Fib, Stago Cat#00673, Asniéres sur Seine, France) was
added post hoc and the measurements were continued for another 30 min to assess fib-
rinogen degradation. Negative controls followed identical methods, except 7 µL of 1:1
glycerol:diH2O replaced venom.
3.5. Statistics
Data were graphed and analysed using GraphPad Prism version 8.0.0 for iOS (Graph-
Pad Software, San Diego, CA, USA). For phospholipid interaction data, curves were fit
using the non-linear regression (linear model or log(agonist) vs. response (three parame-
ters)) with confidence intervals set to 95% and Shapiro–Wilk, Kolmogorov Smirnov and
Q-Q plot diagnostic tests for normality. For linear models, extra sum-of-squares F-tests
(significance set to p < 0.05) were run to compare slope deviation from 0. Venom-fibrinogen
thromboelastography data were tested for normality using Shapiro–Wilk tests and com-
pared to the control using unpaired t-tests. For graphing, the venom data were then
normalised to the thrombin control (100%) and subtracted from 100 to calculate percentage
reduction in functional fibrinogen. For the MTT assays, venom cytotoxicity data were
normalised to the vehicle-treated cells negative control (100%) to calculate the percentage
of viable cells remaining following venom treatment. Data were then tested for normality
using Shapiro–Wilk tests (significance set to p < 0.05) and Q-Q plot diagnostic tests. The
percentages of viable cells were then compared to the control using unpaired t-tests.
4. Conclusions
This study revealed promising avenues for further research into the pharmacological
potential of compounds from these venoms. Each of the Pseudocerastes venoms significantly
reduced the viability of the cancerous MM96L cells while having a limited effect on
healthy NFF cells, showing specificity of these venoms towards tumorous cells. This was
particularly pronounced in the venoms of P. persicus and P. urarachnoides, indicating that
they possess a toxin that shows therapeutic potential for melanoma. Future studies should
be aimed at identifying the toxins and molecular mechanisms underpinning the selective
cytotoxicity of the crude Pseudocerastes venoms in addition to tests on a wider range of
melanoma cell lines of different mutations.
The anticoagulant activities of P. fieldi and P. persicus venoms appeared to be predom-
inately driven by interactions between PLA2s and plasma phospholipids with a limited
degree of fibrinogenolysis. Fibrinolysis was not evident by these venoms. However,
variable actions upon fibrinogen were present, with the possibility of these being novel
mechanisms. Modest evidence indicated that some fibrinogenolytic activity may be me-
diated by E. macmahonii venom phospholipases, which represents an atypical activity for
this toxin class and warrants further investigation. Furthermore, the results suggested
the possibility of a venom-derived serine protease that inhibits fibrinogenolytic activity
in the venom of P. fieldi. The use of drugs in the treatment of clotting disorders and the
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management of bleeding during surgical procedures can be complicated by the absence of
an adequate inhibitor or reversal agent. An optimal treatment could consist of an active
compound paired with a highly specific inhibitor. The fibrinogenolytic toxin and associated
serine protease inhibitor that may be present in this venom could represent the foundations
of such a combinatory treatment/reversal strategy.
While future studies are required to characterise key venom components comprehen-
sively, the bioactive properties of the crude venoms used in this study suggest that they
contain a number of toxins that may be suitable for pharmacological development into
antithrombotic or anticancer agents.
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